# Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

> **NCT05461690** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Homologous Recombination Deficiency
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT05461690
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-07-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05461690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05461690, "Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05461690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*